SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Peter Kerling who wrote (5369)8/26/1998 4:14:00 PM
From: Linda Kaplan  Respond to of 7041
 
No clue. Maybe Biodoc knows? Or Bradpalm1? You're right, if there's a non-approval, the stock will tank big time. Anyway, the market may start to realize what's been said here today: the ED market isn't as big as has been thought; Viagra has almost all the market there is to be had; a lesser drug isn't going to get much, if any, market share, even if approved; Vasomax has a good chance of not being FDA approved.

Linda



To: Peter Kerling who wrote (5369)8/26/1998 4:22:00 PM
From: Tokyo VD  Read Replies (2) | Respond to of 7041
 
Peter,

No one is awaiting FDA approval. That cannot come until a full review of Zonagen's NDA is completed by the FDA. The normal review time is 12 to 18 months (with the FDA now shooting for a 12 month review time frame).

Tokyo


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News